B-MYB is hypophosphorylated and resistant to degradation in neuroblastoma: Implications for cell survival

Blood Cells, Molecules, and Diseases

Volumn 39, Issue 3, 2007, Pages 263-271

  Schwab, Rebekka ^a   Caccamo, Alessandro ^b   Bettuzzi, Saverio ^b   Anderson, John ^a   Sala, Arturo ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF PARMA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

B MYB PROTEIN; ONCOPROTEIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL ACTIVITY; CELL DESTRUCTION; CELL SURVIVAL; CELL TRANSFORMATION; CONTROLLED STUDY; DOWN REGULATION; EWING SARCOMA; GENE INACTIVATION; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; HALF LIFE TIME; HUMAN; HUMAN CELL; NEUROBLASTOMA; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; ULTRAVIOLET RADIATION; WESTERN BLOTTING;

APOPTOSIS; CELL CYCLE PROTEINS; CELL LINE; CELL LINE, TUMOR; CELL SURVIVAL; DNA-BINDING PROTEINS; HUMANS; NEUROBLASTOMA; PHOSPHORYLATION; TRANS-ACTIVATORS; ULTRAVIOLET RAYS;

EID: 34748826133     PISSN: 10799796     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcmd.2007.04.006     Document Type: Article

References (42)

1. Brodeur G.M. Neuroblastoma: biological insights into a clinical enigma. Nat. Rev. Cancer 3 (2003) 203-216
2. Raschella G., Cesi V., Amendola R., et al. Expression of B-MYB in neuroblastoma tumors is a poor prognostic factor independent from MYCN amplification. Cancer Res. 59 (1999) 3365-3368
3. Cervellera M., Raschella G., Santilli G., et al. Direct transactivation of the anti-apoptotic gene apolipoprotein J (clusterin) by B-MYB. J. Biol. Chem. 275 (2000) 21055-21060
4. Oh I.H., and Reddy E.P. The myb gene family in cell growth, differentiation and apoptosis. Oncogene 18 (1999) 3017-3033
5. Sala A. B-MYB, a transcription factor implicated in regulating cell cycle, apoptosis and cancer. Eur. J. Cancer 41 (2005) 2479-2484
6. Tanaka Y., Patestos N.P., Maekawa T., and Ishii S. B-MYB is required for inner cell mass formation at an early stage of development. J. Biol. Chem. 274 (1999) 28067-28070
7. Sala A., and Calabretta B. Regulation of BALB/c 3T3 fibroblast proliferation by B-MYB is accompanied by selective activation of cdc2 and cyclin D1 expression. Proc. Natl. Acad. Sci. U. S. A. 89 (1992) 10415-10419
8. Okada M., Akimaru H., Hou D.X., et al. Myb controls G(2)/M progression by inducing cyclin B expression in the Drosophila eye imaginal disc. EMBO J. 21 (2002) 675-684
9. Zhu W., Giangrande P.H., and Nevins J.R. E2Fs link the control of G1/S and G2/M transcription. EMBO J. 23 (2004) 4615-4626
10. Willis S., Day C.L., Hinds M.G., and Huang D.C. The Bcl-2-regulated apoptotic pathway. J. Cell Sci. 116 (2003) 4053-4056
11. Lang G., Gombert W.M., and Gould H.J. A transcriptional regulatory element in the coding sequence of the human Bcl-2 gene. Immunology 114 (2005) 25-36
12. Zhang H., Kim J.K., Edwards C.A., et al. Clusterin inhibits apoptosis by interacting with activated Bax. Nat. Cell Biol. 7 (2005) 909-915
13. Forozan F., Mahlamaki E.H., Monni O., et al. Comparative genomic hybridization analysis of 38 breast cancer cell lines: a basis for interpreting complementary DNA microarray data. Cancer Res.. 60 (2000) 4519-4525
14. Tanner M.M., Grenman S., Koul A., et al. Frequent amplification of chromosomal region 20q12-q13 in ovarian cancer. Clin. Cancer Res. 6 (2000) 1833-1839
15. Zondervan P.E., Wink J., Alers J.C., et al. Molecular cytogenetic evaluation of virus-associated and non-viral hepatocellular carcinoma: analysis of 26 carcinomas and 12 concurrent dysplasias. J. Pathol. 192 (2000) 207-215
16. Bar-Shira A., Pinthus J.H., Rozovsky U., et al. Multiple genes in human 20q13 chromosomal region are involved in an advanced prostate cancer xenograft. Cancer Res. 62 (2002) 6803-6807
17. Skotheim R.I., Monni O., Mousses S., et al. New insights into testicular germ cell tumorigenesis from gene expression profiling. Cancer Res. 62 (2002) 2359-2364
18. Johnson L.R., Johnson T.K., Desler M., et al. Effects of B-MYB on gene transcription: phosphorylation-dependent activity ans acetylation by p300. J. Biol. Chem. 277 (2002) 4088-4097
19. Santilli G., Schwab R., Watson R., et al. Temperature-dependent modification and activation of B-MYB: Implications for cell survival. J. Biol. Chem. 280 (2005) 15628-15634
20. Nicoletti I., Migliorati G., Pagliacci M.C., et al. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J. Immunol. Methods 139 (1991) 271-279
21. Lipinski M., Braham K., Philip I., et al. Neuroectoderm-associated antigens on Ewing's sarcoma cell lines. Cancer Res. 47 (1987) 183-187
22. Charrasse S., Carena I., Brondani V., et al. Degradation of B-MYB by ubiquitin-mediated proteolysis: involvement of the Cdc34-SCF(p45Skp2) pathway. Oncogene 19 (2000) 2986-2995
23. He J., Xu J., Xu X.X., and Hall R.A. Cell cycle-dependent phosphorylation of Disabled-2 by cdc2. Oncogene 22 (2003) 4524-4530
24. Ley R., Ewings K.E., Hadfield K., et al. Extracellular signal-regulated kinases 1/2 are serum-stimulated "Bim(EL) kinases" that bind to the BH3-only protein Bim(EL) causing its phosphorylation and turnover. J. Biol. Chem. 279 (2004) 8837-8847
25. Lin D., Fiscella M., O'Connor P.M., et al. Constitutive expression of B-MYB can bypass p53-induced Waf1/Cip1-mediated G1 arrest. Proc. Natl. Acad. Sci. U. S. A. 91 (1994) 10079-10083
26. Sala A., Casella I., Bellon T., et al. B-MYB promotes S phase and is a downstream target of the negative regulator p107 in human cells. J. Biol. Chem. 271 (1996) 9363-9367
27. Sala A., De Luca A., Giordano A., and Peschle C. The retinoblastoma family member p107 binds to B-MYB and suppresses its autoregulatory activity. J. Biol. Chem. 271 (1996) 28738-28740
28. Joaquin M., Bessa M., Saville M.K., and Watson R.J. B-MYB overcomes a p107-mediated cell proliferation block by interacting with an N-terminal domain of p107. Oncogene 21 (2002) 7923-7932
29. Joaquin M., and Watson R.J. The cell cycle-regulated B-MYB transcription factor overcomes cyclin-dependent kinase inhibitory activity of p57(KIP2) by interacting with its cyclin-binding domain. J. Biol. Chem. 278 (2003) 44255-44264
30. Grassilli E., Salomoni P., Perrotti D., et al. Resistance to apoptosis in CTLL-2 cells overexpressing B-MYB is associated with B-MYB-dependent bcl-2 induction. Cancer Res. 59 (1999) 2451-2456
31. Williams B.R. Targeting specific cell types with silencing RNA. N. Engl. J. Med. 353 (2005) 1410-1411
32. Sala A., Kundu M., Casella I., et al. Activation of human B-MYB by cyclins. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 532-536
33. Ziebold U., Bartsch O., Marais R., et al. Phosphorylation and activation of B-MYB by cyclin A-Cdk2. Curr. Biol. 7 (1997) 253-260
34. Saville M.K., and Watson R.J. The cell-cycle regulated transcription factor B-MYB is phosphorylated by cyclin A/Cdk2 at sites that enhance its transactivation properties. Oncogene 17 (1998) 2679-2689
35. Bessa M., Saville M.K., and Watson R.J. Inhibition of cyclin A/Cdk2 phosphorylation impairs B-MYB transactivation function without affecting interactions with DNA or the CBP coactivator. Oncogene 20 (2001) 3376-3386
36. Ahlbory D., Appl H., Lang D., and Klempnauer K.H. Disruption of B-MYB in DT40 cells reveals novel function for B-MYB in the response to DNA-damage. Oncogene 24 (2005) 7127-7134
37. Cervellera M.N., and Sala A. Poly(ADP-ribose) polymerase is a B-MYB coactivator. J. Biol. Chem. 275 (2000) 10692-10696
38. Bartusel T., Schubert S., and Klempnauer K.H. Regulation of the cyclin D1 and cyclin A1 promoters by B-MYB is mediated by Sp1 binding sites. Gene 351 (2005) 171-180
39. Cicchillitti L., Jimenez S.A., Sala A., and Saitta B. B-MYB acts as a repressor of human COL1A1 collagen gene expression by interacting with Sp1 and CBF factors in scleroderma fibroblasts. Biochem. J. 378 (2004) 609-616
40. Sala A., Saitta B., De Luca P., et al. B-MYB transactivates its own promoter through SP1-binding sites. Oncogene 18 (1999) 1333-1339
41. Yu X., Caltagarone J., Smith M.A., and Bowser R. DNA damage induces cdk2 protein levels and histone H2B phosphorylation in SH-SY5Y neuroblastoma cells. J. Alzheimer's Dis. 8 (2005) 7-21
42. McKenzie P.P., Guichard S.M., Middlemas D.S., et al. Wild-type p53 can induce p21 and apoptosis in neuroblastoma cells but the DNA damage-induced G1 checkpoint function is attenuated. Clin. Cancer Res. 5 (1999) 4199-4207